WB, IP
H
Endogenous
18, 21, 27
Rabbit IgG
#Q99075
1839
Product Information
Product Usage Information
| Application | Dilution |
|---|---|
| Western Blotting | 1:1000 |
| Immunoprecipitation | 1:50 |
Storage
Specificity / Sensitivity
Species Reactivity:
Human
Source / Purification
Monoclonal antibody is produced by immunizing animals with a recombinant protein fragment specific to human mature HBEGF protein.
Background
Heparin-binding EGF-like growth factor (HBEGF), also known as HB-EGF, belongs to the epidermal growth factor (EGF) family (1). The newly synthesized proHBEGF (about 27 kDa) has an N-terminal prodomain, a heparin-binding EGF domain, and a C-terminal transmembrane fragment (CTF). The heparin-binding region of HBEGF interacts with heparin residues in the extracellular matrix (ECM) and anchors the protein in the ECM. The proHBEGF is activated by the extracellular ADAM and MMP metalloproteases, shedding off its N-terminal prodomain and/or CTF, resulting in a 14-22 kDa product depending on different proteolytic processes. The mature HBEGF acts as a ligand for EGFR or ErbB4 receptors to activate downstream signaling pathways (2,3). The remaining membrane bound CTF is further internalized and binds to Bcl6 to regulate the related nuclear function (3). HBEGF has been shown to be involved in many physiological processes, such as placenta formation (4), heart development and function (5), and hematopoietic cell proliferation (6). The growth factor plays important roles in tissue inflammation, wound healing, and cancer development. Therefore, HBEGF is proposed as a therapeutic target in related diseases (7-10).
- Miyamoto, S. et al. (2006) Cancer Sci 97, 341-7.
- Tsujioka, H. et al. (2010) Anticancer Res 30, 3107-12.
- Higashiyama, S. et al. (2008) Cancer Sci 99, 214-20.
- Jessmon, P. et al. (2009) Mol Reprod Dev 76, 1116-27.
- Iwamoto, R. and Mekada, E. (2006) Cell Struct Funct 31, 1-14.
- Vinante, F. and Rigo, A. (2013) Toxins (Basel) 5, 1180-1201.
- Dao, D.T. et al. (2018) Am J Pathol 188, 2446-2456.
- Eapen, M.S. et al. (2019) Lab Invest 99, 150-157.
- Tsujioka, H. et al. (2011) Curr Opin Obstet Gynecol 23, 24-30.
- Miyata, K. et al. (2012) Anticancer Res 32, 2347-52.
Species Reactivity
Species reactivity is determined by testing in at least one approved application (e.g., western blot).
Western Blot Buffer
IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 5% w/v BSA, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.
Applications Key
WB: Western Blotting IP: Immunoprecipitation
Cross-Reactivity Key
H: human M: mouse R: rat Hm: hamster Mk: monkey Vir: virus Mi: mink C: chicken Dm: D. melanogaster X: Xenopus Z: zebrafish B: bovine Dg: dog Pg: pig Sc: S. cerevisiae Ce: C. elegans Hr: horse GP: Guinea Pig Rab: rabbit All: all species expected
Trademarks and Patents
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.
